Urology Cancer Center

What Urology Cancer Center does

XCancer (formerly Urology Cancer Center) is a private, founder-led community cancer center founded in 2010 by Dr. Luke Nordquist and headquartered at 17607 Gold Plaza in Omaha, Nebraska. The center is described as the only U.S. facility exclusively dedicated to urologic cancers—principally prostate, kidney, and bladder—with a patient base of more than 400 individuals per month drawn from 42+ states and 7 countries.

The operating model is a vertically integrated, single-site platform that co-locates eight service modules under one roof: standard-of-care cancer treatment, a Theranostics & Radiopharmaceuticals program (including Lutetium-PSMA-617), telemedicine visits, an in-house imaging center, a CAP/CLIA-certified clinical laboratory delivering same-day PSA results on roughly 11,000 specimens per year, a medically integrated dispensary in which the prescribing physician also dispenses medications, insurance counseling, and a Phase I–III clinical research center with documented access to over 1,300 active prostate cancer clinical trials and milestones of 20 First-in-World, 21 First-in-U.S., and 15 First-in-Human treatments. The center is one of only three primary U.S. sites chosen for radiopharmaceutical clinical research alongside Memorial Sloan Kettering and Tulane University.

Revenue is generated through (i) fee-for-service billing of cancer treatments, imaging, and laboratory diagnostics to Medicare and private payers; (ii) clinical-trial revenue and sponsor-funded research operations with pharmaceutical companies, including investigational drug supply at no charge to patients; and (iii) indirect revenue capture via coordination with over 20 patient assistance foundations that absorb roughly $6 million of annual treatment cost for eligible patients. Go-to-market is sales-led, driven by physician referrals (notably from Mayo Clinic), patient testimonials across web and third-party review platforms, and event-driven patient education; telemedicine extends reach nationally. The company is privately held with no disclosed external funding, parent company, or institutional investors, and operates with an 11–50 employee headcount.

Name

Urology Cancer Center

Legal name

XCancer

Website

https://gucancer.com

Company type

Private

Founded year

2010

Operating status

Operating

Headcount range

11–50 employees

Short description

XCancer (formerly Urology Cancer Center) is a private, founder-led community cancer center in Omaha, Nebraska, exclusively dedicated to prostate and urologic cancers, delivering integrated clinical care, radiopharmaceutical therapy, imaging, lab, pharmacy, telemedicine, insurance counseling, and Phase I–III clinical research to 400+ monthly patients from over 42 states and 7 countries.

Ownership category

akta.pro rank

Product category

Oncology Services

NAICS

Offices of Physicians (62111), Diagnostic Imaging Centers (621512)

SIC

Services-Offices & Clinics Of Doctors Of Medicine (8011), Services-Specialty Outpatient Facilities, Nec (8093), Services-Medical Laboratories (8071)

akta.pro primary industry

Urologic Oncology (HLAKAOAB)

akta.pro secondary industries

Nuclear Medicine Clinical Services & Therapy Centers (HLAIAGAI), Oncology Telemedicine Platforms (HLALAGAH), Genitourinary Oncology (HLAKAFAM)

Keywords

• Prostate cancer treatment
• Urologic cancer care
• Radiopharmaceutical therapy
• Clinical trial research
• Community oncology center

Headquarters

HQ city

Omaha

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales, Supply Chain

Revenue model

1. Patient Treatment Services: Fee-for-service billing for cancer treatments, diagnostic tests, imaging, and laboratory services billed to patient insurance plans. Standard-of-care FDA-approved treatments covered through Medicare and private insurance.
2. Clinical Trial Research: Clinical trial treatments provided at no cost to patients with pharmaceutical sponsors covering investigational drug costs. FDA-approved medications on trials may be billed to insurance or covered by study.
3. Patient Assistance Programs: Annual provision of approximately $6 million in free cancer care to patients. Access to 20+ patient assistance foundations and pharmaceutical company support programs to cover treatment costs for eligible patients.

Pricing tiers

Go-to-market motion2 records

Distribution channels3 records

Marketing channels4 records

Core offering

XCancer (formerly Urology Cancer Center) is a private community cancer center in Omaha, Nebraska, exclusively dedicated to prostate and urologic cancers. It provides FDA-approved standard-of-care oncology treatments, access to over 1,300 clinical trials (including radiopharmaceutical therapies such as Lutetium-PSMA-617), and integrated support services (imaging, certified laboratory, on-site pharmacy dispensary, telemedicine, and insurance/financial counseling) under a single-roof care model.

Product overview

XCancer (formerly Urology Cancer Center) is a single-location community cancer center in Omaha, Nebraska, exclusively dedicated to prostate and urologic cancers since 2010. Founded by Dr. Luke Nordquist, the center operates as an integrated care platform combining eight core service modules: Cancer Care (standard-of-care treatments), Theranostics & Radiopharmaceuticals (targeted radiopharmaceutical therapies), Telemedicine (remote consultations), Imaging Center (diagnostic imaging), Medically Integrated Dispensary (on-site pharmacy with Dr. Luke as both prescriber and pharmacist), CLIA/CAP-certified Laboratory (same-day PSA and genetic testing), Insurance Counseling (financial assistance and copay programs), and Research Center (access to 1,300+ clinical trials). The Medically Integrated Dispensary provides unique same-day prescription fulfillment with the prescribing physician also serving as pharmacist. The center differentiates through extensive clinical trial access, having been selected as one of only three U.S. sites for leading radiopharmaceutical trials alongside Memorial Sloan Kettering and Tulane University.

Differentiator

Problem solved

Functional benefit

Products and services

• Cancer Care Comprehensive cancer treatment services providing FDA-approved standard-of-care treatments for prostate and urologic cancers, including access to cutting-edge clinical research trials, delivered at the Omaha center to patients from over 42 states and 7 countries.
• Theranostics & Radiopharmaceuticals Advanced radiopharmaceutical treatments including Lutetium-PSMA-617 therapy and other targeted radionuclide therapies for prostate cancer, delivered through clinical trials and standard care as part of an FDA-approved and investigational theranostics program.
• Telemedicine Remote consultation and follow-up services allowing patients to receive expert cancer care and second opinions from Dr. Nordquist and the care team without traveling to the Omaha location.
• Imaging Center On-site diagnostic imaging services for cancer diagnosis, staging, and treatment monitoring, providing rapid results to support timely treatment decisions.
• Medically Integrated Dispensary On-site pharmacy where the prescribing physician (Dr. Luke) also serves as pharmacist, providing same-day prescription services, financial assistance navigation, and copay support programs for cancer medications.
• Laboratory CLIA-certified and CAP-accredited clinical laboratory providing same-day PSA results, CBC, testosterone, creatinine, urinalysis, and genetic mutation analysis (Next Generation Sequencing) for approximately 11,000 specimens annually.
• Insurance Counseling Financial and insurance counseling services with access to over 20 patient assistance foundations, helping patients navigate insurance coverage, obtain prior authorizations, and minimize out-of-pocket costs for cancer treatment.
• Research Center (Clinical Trials) Extensive clinical research program providing access to over 1,300 active prostate cancer clinical trials and access to cutting-edge treatments before FDA approval, including radiopharmaceutical trials.

Quantifiable outcome

• 20 First-in-World, 21 First-in-U.S., 15 First-in-Human treatments achieved
• +3 more outcomes

Named customers5 records

Segments3 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Five partnerships are on record, tiered core and major.

• Memorial Sloan Kettering Cancer CentercoreStrategic or Co-development PartnerOne of only 3 primary U.S. sites chosen by pharmaceutical companies for radiopharmaceutical clinical research trials, alongside Memorial Sloan Kettering in NYC and Tulane University in New Orleans.
• Tulane UniversitycoreStrategic or Co-development PartnerOne of only 3 primary U.S. sites chosen by pharmaceutical companies for radiopharmaceutical clinical research trials, alongside Memorial Sloan Kettering and XCancer Omaha.
• Mayo ClinicmajorChannel Partner/ Reseller/ DistributorMajor referral source for patients seeking clinical trial options and expert second opinions. Patient testimonials specifically mention referrals from Mayo Clinic for advanced prostate cancer treatment.
• Patient Assistance FoundationscoreOthersAccess to over 20 patient assistance foundations helping patients afford cancer treatments. XCancer's financial team works to obtain millions in patient assistance annually.
• Pharmaceutical CompaniescoreStrategic or Co-development PartnerPharmaceutical sponsors hand-pick XCancer to conduct clinical research trials due to exceptional research quality, volume, focus, and accrual rates. Dr. Nordquist often given right of first refusal for promising studies.

Scale indicators6 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• The US Oncology Network (McKesson): Network of more than 1,400 independent community oncology physicians organized for group purchasing, clinical research, and practice operations support. Comparable as a community oncology delivery model with significant trial infrastructure, though much larger and more diversified than XCancer.
• Florida Cancer Specialists & Research Institute: Large, physician-owned community oncology practice combining standard-of-care treatment with an integrated Phase I clinical research program across multiple Florida locations. Closely comparable in combining community-based delivery, in-house research, and integrated ancillaries like imaging, lab, and dispensing.
• OneOncology: Platform partnership model for community oncology practices, providing capital, technology, research, and operational scale to independent oncology groups. Comparable in combining independent community oncology economics with centralized clinical trial access and integrated ancillaries.
• Genesis Healthcare Partners: Specialty urology and oncology practice network offering advanced urologic cancer treatments including theranostics and clinical trials in California. Most directly comparable peer given shared urologic-oncology specialty focus and radiopharmaceutical capability, though larger and geographically broader.
• New York Cancer & Blood Specialists: Physician-owned community oncology and hematology practice with multiple locations, on-site imaging and lab, and an active clinical trials program. Closely mirrors XCancer's integrated community-based delivery model with research depth, at a larger geographic scale.
• Tennessee Oncology: Physician-led community oncology and hematology practice operating across Tennessee with a deep clinical research program and integrated services including imaging, lab, and pharmacy. Directly comparable specialty oncology + research model to XCancer, though broader in tumor-type scope.
• Compass Oncology (US Oncology Network affiliate): Community-based medical oncology, hematology, radiation oncology, and urology practice across Oregon and Washington with a dedicated clinical research program. Comparable multi-modality community cancer care model with research and ancillaries integrated.

Broad incumbents

• Lantheus Holdings: Commercial-stage radiopharmaceutical company with the leading PSMA diagnostic (Pylarify) used in prostate cancer imaging and a growing therapeutic pipeline. Comparable as a radiopharmaceutical ecosystem participant in prostate cancer, though operating as a manufacturer/sponsor rather than treatment-delivery site.
• Cancer Treatment Centers of America / City of Hope: Integrated cancer specialty hospital and outpatient network offering standard-of-care and clinical trials, with particular depth in advanced and complex cancers. Comparable as a destination cancer center model attracting patients from across the U.S., but at significantly larger institutional scale than XCancer.
• Novartis (Pluvicto / Lutetium-177 PSMA-617): Pharmaceutical sponsor of Lutetium-PSMA-617 (Pluvicto), the radioligand therapy that XCancer's research program helped pioneer through early clinical trials. Indirectly comparable as the incumbent driving demand for the radiopharmaceutical trials XCancer conducts.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat7 records

Key risks6 records

Key highlights7 records

Customer concentration

• Facebookfacebook.com/UrologyCancerCenterandGUResearchNetwork
• LinkedInlinkedin.com/company/urology-cancer-center-pc

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Urology Cancer Center